INTRAVITREAL RITUXIMAB AS TREATMENT FOR INTRAOCULAR LYMPHOMA Naon Kim Karla P Gonzales Farro Pablo Gili Manzanaro Mª Carmen García Saénz.
CASE REPORT 56-year-old woman visual loss in her right eye Personal history: Breast B cell Non Hodgkin Lymphoma ( complete remission in 2011 with R-CHOP+ Radiotherapy) Autoinmune Encephalitis with intracraneal space occupying lesions compatible with lymphoma ? (intracraneal biopsy- , cerebrospinal fluid -) Treated with metotrexate (2013)
Color funduscopy Visual acuity Right eye:0,2 Left eye:0,7 BMC: vitreous tyndall RE Funduscopy: multiple yellow lesions Color funduscopy
Green filter Color AGF ICG
OCT Cirrus
CASE REPORT (cytology, flow cytometry) Diagnostic 23G pars plana vitrectomy No conclusive results (cytology, flow cytometry) Treatment: No systemic treatment indicated since anatomic pathology was negative Ocular treatment options: Intravitreal Metotrexate Intravitreal Rituximab(1 mg/0,1 mL) monthly x 4
After Rituximab (1 mg/0,1 mL) monthly x 4
Visual acuity after treatment RE: 0,7
rituximab CONCLUSIONS Rituximab has been used for treating systemic lymphoma and other inflammatory conditions. Eventhough the diagnosis of intraocular of lymphoma was not certain (AP -), intravitreal rituximab has brought excellent results. Rituximab can be considered a good alternative for intraocular lymphoma treatment